Press coverage about Biocept (NASDAQ:BIOC) has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biocept earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 45.6687405340408 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
BIOC has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Biocept from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd. Chardan Capital restated a “buy” rating and set a $1.50 price objective (down previously from $2.50) on shares of Biocept in a research report on Tuesday, November 14th. Finally, ValuEngine upgraded shares of Biocept from a “strong sell” rating to a “sell” rating in a research report on Monday, October 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Biocept currently has an average rating of “Hold” and a consensus target price of $2.25.
Shares of Biocept (BIOC) opened at $0.72 on Friday. Biocept has a twelve month low of $0.60 and a twelve month high of $2.76. The company has a market cap of $21.79, a P/E ratio of -0.81 and a beta of 2.77. The company has a current ratio of 1.41, a quick ratio of 1.27 and a debt-to-equity ratio of 0.24.
WARNING: This piece of content was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/12/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-biocept-bioc-share-price.html.
Biocept Company Profile
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.